Kiniksa Pharmaceuticals (KNSA)

• Market cap: $3.15B
• 1 day: -0.1%
• 5 days: 0.48%
• 1 month: 0.36%
• 3 months: 13.65%
• 6 months: 46.25%
• Year to date: 108.38%
• 1 year: 104.48%
• 5 years: 112.21%
• 10 years: 113.41%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315